title: A combined therapeutic modality with hyperthermia and locally administered rIFN-beta inhibited the growth of B16 melanoma in association with the modulation of cellular infiltrates.
abstract: Murine B16-F10 melanoma was treated with local microwave hyperthermia, local injection of murine recombinant interferon-beta (rIFN-beta) or a combination of both in order to investigate the augmentation of anti-proliferative effects with this combination treatment. Concerning the local modulation of immunological reactions of the host, local hyperthermia at 43 degrees C for 15 min on murine melanoma caused remarkable infiltration of natural killer cells and local injection of rIFN-beta led to considerable infiltration of T cells. When these two modalities were combined, the infiltration of NK cells completely disappeared and, instead, remarkable augmentation of T cell infiltration occurred. Synergistic suppressive effects on melanoma growth with occasional scar formation were seen with this combined modality. These results indicate that local hyperthermia with a combination of rIFN-beta modulates local immune reactions of the host, and probably this immune reaction is partly involved in the course of the suppression of tumor growth.
authors.affiliation: Department of Dermatology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Toyofuku
authors.forename: A
authors.initials: A
authors.lastname: Urabe
authors.forename: S
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Hori
mesh_terms: D000818:Animals; D002455:Cell Division / Q000502:physiology; D002465:Cell Movement; D003131:Combined Modality Therapy; D006979:Hyperthermia, Induced; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use*; D008546:Melanoma, Experimental / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008872:Microwaves; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000473:pathology / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D011994:Recombinant Proteins; D016899:Interferon-beta